Lega Sara, Badina Laura, De Leo Luigina, Andrade Stefanny, Ziberna Fabiana, Gaita Bartolomea, Di Leo Grazia, Bramuzzo Matteo, Barbi Egidio, Not Tarcisio, Berti Irene
From the Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy.
the Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
J Pediatr Gastroenterol Nutr. 2023 Jan 1;76(1):43-48. doi: 10.1097/MPG.0000000000003629. Epub 2022 Sep 29.
An increased frequency of celiac disease (CeD) has been reported in severe Immunoglobulin E (IgE) -mediated food allergy (FA). This observation requires confirmation, and whether CeD affects FA severity and resolution is unknown. The study aims to estimate the prevalence of CeD in patients with FA and to investigate whether CeD affects FA severity and oral tolerance.
Consecutive patients with FA referred for allergen reintroduction, either to evaluate allergy resolution or to start oral immunotherapy (OIT), were evaluated for CeD and for FA severity. The primary outcome was the prevalence of CeD. Secondary outcomes were the frequency of severe FA and the level of clinical tolerance at study entry and at last follow-up in patients with isolated FA versus patients with FA + CeD.
Two hundred twenty-eight patients were included. CeD was confirmed in 15 patients (6.6%) of whom, 8 patients had a previously established diagnosis of CeD and were on a gluten-free diet. Severe FA was observed in 12 patients with FA + CeD (80%) versus 88 patients with FA (42%) ( P = 0.006). At baseline, patients with FA + CeD had significantly higher median allergen-specific IgE levels [61.8 kU/L; interquartile range (IQR) 11.6-279.0] compared to patients with FA (20.3 kU/L; IQR 2.9-72.7) ( P < 0.001). Complete clinical tolerance was observed in 1 of 15 patients (7%) with FA + CeD versus 98 of 205 patients (48%) with FA ( P = 0.002).
CeD is highly prevalent in patients with FA and could affect FA severity and response to OIT. CeD screening should be considered in patients with severe or persistent FA.
据报道,在严重的免疫球蛋白E(IgE)介导的食物过敏(FA)中,乳糜泻(CeD)的发病率有所增加。这一观察结果需要得到证实,且CeD是否会影响FA的严重程度和缓解情况尚不清楚。本研究旨在估计FA患者中CeD的患病率,并调查CeD是否会影响FA的严重程度和口服耐受性。
对连续转诊进行过敏原重新引入的FA患者进行评估,以评估过敏缓解情况或开始口服免疫治疗(OIT),同时评估CeD和FA严重程度。主要结局是CeD的患病率。次要结局是单纯FA患者与FA+CeD患者在研究入组时和最后一次随访时严重FA的频率以及临床耐受水平。
共纳入228例患者。15例患者(6.6%)确诊为CeD,其中8例患者先前已确诊CeD并接受无麸质饮食。12例FA+CeD患者(80%)出现严重FA,而88例FA患者(42%)出现严重FA(P = 0.006)。基线时,FA+CeD患者的过敏原特异性IgE水平中位数[61.8 kU/L;四分位间距(IQR)11.6 - 279.0]显著高于FA患者(20.3 kU/L;IQR 2.9 - 72.7)(P < 0.001)。15例FA+CeD患者中有1例(7%)实现完全临床耐受,而205例FA患者中有98例(48%)实现完全临床耐受(P = 0.002)。
CeD在FA患者中高度流行,可能影响FA的严重程度和对OIT的反应。对于严重或持续性FA患者,应考虑进行CeD筛查。